将基因组改变与癌症生物学联系起来的蛋白质组学：NCI 临床蛋白质组肿瘤分析联盟。
Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium.
机构信息
1Division of Oncology and 2Division of Endocrinology and Metabolism, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri; 3The Broad Institute of MIT and Harvard, Cambridge, Massachusetts; 4Fred Hutchinson Cancer Research Center, Seattle; 5Biological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington; 6Office of Cancer Clinical Proteomics Research, National Cancer Institute, NIH, Bethesda, Maryland; and 7The Jim Ayers Institute for Cancer Detection and Diagnosis, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
出版信息
Cancer Discov. 2013 Oct;3(10):1108-12. doi: 10.1158/2159-8290.CD-13-0219.
Abstract
The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium is applying the latest generation of proteomic technologies to genomically annotated tumors from The Cancer Genome Atlas (TCGA) program, a joint initiative of the NCI and the National Human Genome Research Institute. By providing a fully integrated accounting of DNA, RNA, and protein abnormalities in individual tumors, these datasets will illuminate the complex relationship between genomic abnormalities and cancer phenotypes, thus producing biologic insights as well as a wave of novel candidate biomarkers and therapeutic targets amenable to verification using targeted mass spectrometry methods.
摘要
美国国家癌症研究所（NCI）临床蛋白质组肿瘤分析联盟正在将最新一代蛋白质组技术应用于癌症基因组图谱（TCGA）计划中基因组注释的肿瘤，这是 NCI 和国家人类基因组研究所的联合倡议。通过提供个体肿瘤中 DNA、RNA 和蛋白质异常的全面综合说明，这些数据集将阐明基因组异常与癌症表型之间的复杂关系，从而产生生物学见解以及一系列新的候选生物标志物和治疗靶点，这些靶点可使用靶向质谱方法进行验证。
相似文献
1
Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium.将基因组改变与癌症生物学联系起来的蛋白质组学：NCI 临床蛋白质组肿瘤分析联盟。
Cancer Discov. 2013 Oct;3(10):1108-12. doi: 10.1158/2159-8290.CD-13-0219.
2
Integration and Analysis of CPTAC Proteomics Data in the Context of Cancer Genomics in the cBioPortal.CPTAC 蛋白质组学数据在 cBioPortal 癌症基因组学背景下的整合与分析。
Mol Cell Proteomics. 2019 Sep;18(9):1893-1898. doi: 10.1074/mcp.TIR119.001673. Epub 2019 Jul 15.
3
New cancer biomarkers deriving from NCI early detection research.源自美国国立癌症研究所早期检测研究的新型癌症生物标志物。
Recent Results Cancer Res. 2003;163:72-84; discussion 264-6. doi: 10.1007/978-3-642-55647-0_7.
4
NCI's Proteomic Data Commons: A Cloud-Based Proteomics Repository Empowering Comprehensive Cancer Analysis through Cross-Referencing with Genomic and Imaging Data.NCI 的蛋白质组学数据联合：一个基于云的蛋白质组学存储库，通过与基因组和成像数据的交叉引用，为全面癌症分析提供支持。
Cancer Res Commun. 2024 Sep 1;4(9):2480-2488. doi: 10.1158/2767-9764.CRC-24-0243.
5
Cancer Proteomics and the Elusive Diagnostic Biomarkers.癌症蛋白质组学与难以捉摸的诊断生物标志物。
Proteomics. 2019 Nov;19(21-22):e1800445. doi: 10.1002/pmic.201800445. Epub 2019 Aug 7.
6
The CPTAC Data Portal: A Resource for Cancer Proteomics Research.CPTAC数据门户：癌症蛋白质组学研究资源
J Proteome Res. 2015 Jun 5;14(6):2707-13. doi: 10.1021/pr501254j. Epub 2015 May 4.
7
1st NCI annual meeting on Clinical Proteomic Technologies for Cancer.美国国立癌症研究所第一届癌症临床蛋白质组学技术年会。
Expert Rev Proteomics. 2008 Feb;5(1):17-20. doi: 10.1586/14789450.5.1.17.
8
Proteogenomic characterization of human colon and rectal cancer.人类结肠癌和直肠癌的蛋白质基因组学特征分析
Nature. 2014 Sep 18;513(7518):382-7. doi: 10.1038/nature13438. Epub 2014 Jul 20.
9
End of cancer-genome project prompts rethink.癌症基因组计划的结束引发了重新思考。
Nature. 2015 Jan 8;517(7533):128-9. doi: 10.1038/517128a.
10
Integrative Proteo-genomic Analysis to Construct CNA-protein Regulatory Map in Breast and Ovarian Tumors.整合蛋白质基因组分析构建乳腺癌和卵巢肿瘤的 CNA-蛋白调控图谱。
Mol Cell Proteomics. 2019 Aug 9;18(8 suppl 1):S66-S81. doi: 10.1074/mcp.RA118.001229. Epub 2019 Jul 7.
引用本文的文献
1
Revealing genetic drivers of ovarian cancer and chemoresistance: insights from whole-genome CRISPR-knockout library screens.揭示卵巢癌及化疗耐药的遗传驱动因素：来自全基因组CRISPR敲除文库筛选的见解
Cell Oncol (Dordr). 2025 Aug 28. doi: 10.1007/s13402-025-01102-4.
2
Integrative proteogenomic characterization of Wilms tumor.肾母细胞瘤的综合蛋白质基因组特征分析
Nat Commun. 2025 Aug 19;16(1):7715. doi: 10.1038/s41467-025-62234-7.
3
Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer.蛋白质基因组学特征揭示了与肌肉浸润性膀胱癌化疗耐药相关的生物标志物。
Cell Rep Med. 2025 Aug 19;6(8):102255. doi: 10.1016/j.xcrm.2025.102255. Epub 2025 Jul 31.
4
Comprehensive pan-cancer multi-omics analysis of ATAD2 in human cancers.ATAD2在人类癌症中的综合泛癌多组学分析。
Medicine (Baltimore). 2025 Jul 18;104(29):e42396. doi: 10.1097/MD.0000000000042396.
5
Integrative multi-omics characterization of 12 syngeneic mouse models.12种同基因小鼠模型的整合多组学特征分析
iScience. 2025 Jun 27;28(8):113024. doi: 10.1016/j.isci.2025.113024. eCollection 2025 Aug 15.
6
Exploring the oncogenic impact of heteroplasmic truncating mutations.探索异质性截短突变的致癌影响。
Mitochondrial Commun. 2025;3:26-43. doi: 10.1016/j.mitoco.2025.03.001. Epub 2025 Mar 26.
7
Identifying and evaluating understudied protein kinases using biological and chemical criteria.使用生物学和化学标准鉴定和评估研究不足的蛋白激酶。
RSC Med Chem. 2025 Jun 5. doi: 10.1039/d5md00306g.
8
Comprehensive evaluation of phosphoproteomic-based kinase activity inference.基于磷酸化蛋白质组学的激酶活性推断的综合评估。
Nat Commun. 2025 May 22;16(1):4771. doi: 10.1038/s41467-025-59779-y.
9
P4HA1 Mediates Hypoxia-Induced Invasion in Human Pancreatic Cancer Organoids.P4HA1介导人胰腺癌类器官中的缺氧诱导侵袭。
Cancer Res Commun. 2025 May 1;5(5):881-895. doi: 10.1158/2767-9764.CRC-24-0025.
10
Stabilization of GTSE1 by cyclin D1-CDK4/6-mediated phosphorylation promotes cell proliferation with implications for cancer prognosis.细胞周期蛋白D1 - CDK4/6介导的磷酸化作用对GTSE1的稳定化促进细胞增殖，这对癌症预后具有重要意义。
Elife. 2025 Apr 24;13:RP101075. doi: 10.7554/eLife.101075.
本文引用的文献
1
Integrative omics analysis reveals the importance and scope of translational repression in microRNA-mediated regulation.整合组学分析揭示了翻译抑制在 microRNA 介导的调控中的重要性和范围。
Mol Cell Proteomics. 2013 Jul;12(7):1900-11. doi: 10.1074/mcp.M112.025783. Epub 2013 Apr 2.
2
Molecular pathways: extracting medical knowledge from high-throughput genomic data.分子通路：从高通量基因组数据中提取医学知识。
Clin Cancer Res. 2013 Jun 15;19(12):3114-20. doi: 10.1158/1078-0432.CCR-12-2093. Epub 2013 Feb 21.
3
The genomic landscape of breast cancer as a therapeutic roadmap.乳腺癌的基因组图谱作为治疗蓝图。
Cancer Discov. 2013 Jan;3(1):27-34. doi: 10.1158/2159-8290.CD-12-0462.
4
Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry.靶向质谱法在生物医学中对肽和蛋白质的定量分析。
Nat Methods. 2013 Jan;10(1):28-34. doi: 10.1038/nmeth.2309.
5
High-throughput SISCAPA quantitation of peptides from human plasma digests by ultrafast, liquid chromatography-free mass spectrometry.通过超快、无液相色谱的质谱法对人血浆消化物中的肽进行高通量 SISCAPA 定量分析。
J Proteome Res. 2012 Dec 7;11(12):5642-9. doi: 10.1021/pr300652v. Epub 2012 Nov 19.
6
Comprehensive molecular portraits of human breast tumours.人类乳腺肿瘤的全面分子特征图谱。
Nature. 2012 Oct 4;490(7418):61-70. doi: 10.1038/nature11412. Epub 2012 Sep 23.
7
Targeted proteomic quantification on quadrupole-orbitrap mass spectrometer.四极杆轨道阱质谱仪上的靶向蛋白质组定量分析。
Mol Cell Proteomics. 2012 Dec;11(12):1709-23. doi: 10.1074/mcp.O112.019802. Epub 2012 Sep 7.
8
Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum.无抗体、靶向的质谱定量分析方法，可在人血浆/血清中低至皮克/毫升级别的蛋白质进行定量分析。
Proc Natl Acad Sci U S A. 2012 Sep 18;109(38):15395-400. doi: 10.1073/pnas.1204366109. Epub 2012 Sep 4.
9
GeLC-MRM quantitation of mutant KRAS oncoprotein in complex biological samples.在复杂生物样本中使用 GeLC-MRM 定量检测突变型 KRAS 癌蛋白
J Proteome Res. 2012 Jul 6;11(7):3908-13. doi: 10.1021/pr300161j. Epub 2012 Jun 26.
10
Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions.基于选择反应监测的蛋白质组学：工作流程、潜力、陷阱和未来方向。
Nat Methods. 2012 May 30;9(6):555-66. doi: 10.1038/nmeth.2015.
Zotero 插件